Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.20
NAS:ACET's Cash-to-Debt is ranked lower than
86% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. NAS:ACET: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACET' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 3.46 Max: 83.22
Current: 0.2
0.16
83.22
Equity-to-Asset 0.25
NAS:ACET's Equity-to-Asset is ranked lower than
80% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:ACET: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.67 Max: 0.77
Current: 0.25
0.25
0.77
Debt-to-Equity 1.57
NAS:ACET's Debt-to-Equity is ranked lower than
79% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NAS:ACET: 1.57 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ACET' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.06 Max: 1.57
Current: 1.57
0
1.57
Debt-to-EBITDA -1.56
NAS:ACET's Debt-to-EBITDA is ranked lower than
78% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NAS:ACET: -1.56 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ACET' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.56  Med: 1.47 Max: 6.22
Current: -1.56
-1.56
6.22
Interest Coverage 0.73
NAS:ACET's Interest Coverage is ranked lower than
94% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 132.39 vs. NAS:ACET: 0.73 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ACET' s Interest Coverage Range Over the Past 10 Years
Min: 0.73  Med: 14.73 Max: 147.43
Current: 0.73
0.73
147.43
Piotroski F-Score: 3
Altman Z-Score: 0.09
Beneish M-Score: -2.59
WACC vs ROIC
6.80%
1.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 2.09
NAS:ACET's Operating Margin % is ranked lower than
61% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. NAS:ACET: 2.09 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ACET' s Operating Margin % Range Over the Past 10 Years
Min: 2.09  Med: 5.83 Max: 10.39
Current: 2.09
2.09
10.39
Net Margin % -28.23
NAS:ACET's Net Margin % is ranked lower than
72% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:ACET: -28.23 )
Ranked among companies with meaningful Net Margin % only.
NAS:ACET' s Net Margin % Range Over the Past 10 Years
Min: -28.23  Med: 3.79 Max: 6.22
Current: -28.23
-28.23
6.22
ROE % -57.26
NAS:ACET's ROE % is ranked lower than
69% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. NAS:ACET: -57.26 )
Ranked among companies with meaningful ROE % only.
NAS:ACET' s ROE % Range Over the Past 10 Years
Min: -57.26  Med: 10.25 Max: 13.54
Current: -57.26
-57.26
13.54
ROA % -20.97
NAS:ACET's ROA % is ranked lower than
67% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. NAS:ACET: -20.97 )
Ranked among companies with meaningful ROA % only.
NAS:ACET' s ROA % Range Over the Past 10 Years
Min: -20.97  Med: 6.01 Max: 7.33
Current: -20.97
-20.97
7.33
ROC (Joel Greenblatt) % -125.82
NAS:ACET's ROC (Joel Greenblatt) % is ranked higher than
56% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. NAS:ACET: -125.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACET' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -125.82  Med: 34.83 Max: 81.35
Current: -125.82
-125.82
81.35
3-Year Revenue Growth Rate 3.10
NAS:ACET's 3-Year Revenue Growth Rate is ranked lower than
58% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:ACET: 3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ACET' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 5.7 Max: 14.9
Current: 3.1
0.9
14.9
3-Year EBITDA Growth Rate -3.20
NAS:ACET's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. NAS:ACET: -3.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ACET' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24  Med: 7.1 Max: 55.1
Current: -3.2
-24
55.1
3-Year EPS without NRI Growth Rate -30.00
NAS:ACET's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. NAS:ACET: -30.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ACET' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30  Med: 6.9 Max: 59.8
Current: -30
-30
59.8
GuruFocus has detected 2 Warning Signs with Aceto Corp NAS:ACET.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACET's 30-Y Financials

Financials (Next Earnings Date: 2018-08-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ACET Guru Trades in Q2 2017

Ken Fisher 138,018 sh (+32.90%)
Chuck Royce 146,600 sh (unchged)
» More
Q3 2017

ACET Guru Trades in Q3 2017

Jim Simons 268,200 sh (New)
HOTCHKIS & WILEY 16,879 sh (New)
Chuck Royce 934,943 sh (+537.75%)
Ken Fisher 154,668 sh (+12.06%)
» More
Q4 2017

ACET Guru Trades in Q4 2017

Joel Greenblatt 20,551 sh (New)
HOTCHKIS & WILEY 154,028 sh (+812.54%)
Ken Fisher 185,709 sh (+20.07%)
Chuck Royce 1,109,995 sh (+18.72%)
Jim Simons 232,700 sh (-13.24%)
» More
Q1 2018

ACET Guru Trades in Q1 2018

Chuck Royce 1,147,152 sh (+3.35%)
HOTCHKIS & WILEY 154,028 sh (unchged)
Joel Greenblatt 19,274 sh (-6.21%)
Ken Fisher 154,574 sh (-16.77%)
Jim Simons 123,300 sh (-47.01%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Reduce -16.77%$7.03 - $11.82 $ 4.00-55%154,574
Joel Greenblatt 2018-03-31 Reduce -6.21%$7.03 - $11.82 $ 4.00-55%19,274
Ken Fisher 2017-12-31 Add 20.07%$9 - $11.69 $ 4.00-62%185,709
HOTCHKIS & WILEY 2017-12-31 Add 812.54%0.01%$9 - $11.69 $ 4.00-62%154,028
Joel Greenblatt 2017-12-31 New Buy$9 - $11.69 $ 4.00-62%20,551
Ken Fisher 2017-09-30 Add 12.06%$10.28 - $17.08 $ 4.00-71%154,668
HOTCHKIS & WILEY 2017-09-30 New Buy$10.28 - $17.08 $ 4.00-71%16,879
Ken Fisher 2017-06-30 Add 32.90%$13.75 - $16.06 $ 4.00-73%138,018
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:ROCO:6562, NAS:MEIP, ROCO:4191, XCNQ:GLH, KAR:MACTER, TSX:CPH, XCNQ:EAT, HKSE:01498, ROCO:4168, LSE:SIS, OTCPK:CVSI, OTCPK:ELTP, BSE:BIO, NAS:JNP, OSTO:PLED, XKRX:900120, OSTO:ERMA, XKRX:018620, TSXV:NINE, XKLS:2879 » details
Traded in other countries:AZJ.Germany,
Headquarter Location:USA
Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Top Ranked Articles about Aceto Corp

SHAREHOLDER ALERT – ACET MFGP PPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ALGT, ACET, MIC and INWK
The Law Offices of Howard G. Smith Reminds Investors of June 25th Deadline in the Class Action Lawsuit Against ACETO Corporation (ACET)
FINAL SHAREHOLDER DEADLINE NOTICE: Class Action Lawsuit Filed Against Aceto Corp. – ACET
Hagens Berman Reminds Investors in Aceto Corporation (ACET) of the June 25, 2018 Securities Class Action Lead Plaintiff Deadline
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Actions Involving Myriad Genetics, Inc., Allegiant Travel Company, Aceto Corporation, and Gridsum Holding Inc.
ACETO SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Aceto Corporation - ACET
UPDATE -- The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Fluor Corporation, Aceto Corporation, Prothena Corporation, Allegiant Travel Company, and Myriad Genetics, Inc.
The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Fluor Corporation, Aceto Corporation, Prothena Corporation, Allegiant Travel Company, and Myriad Genetics, Inc.
Lifshitz & Miller LLP Announces Investigation of ACETO Corporation, Esperion Therapeutics, Inc., Flex Ltd., Kulicke and Soffa Industries, Inc., Macquarie Infrastructure Corporation, Mercury Systems, Inc., Ormat Technologies, Inc., and Prothena Corporation

Ratios

vs
industry
vs
history
Forward PE Ratio 6.82
ACET's Forward PE Ratio is ranked higher than
93% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. ACET: 6.82 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.60
ACET's PB Ratio is ranked higher than
96% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACET: 0.60 )
Ranked among companies with meaningful PB Ratio only.
ACET' s PB Ratio Range Over the Past 10 Years
Min: 0.38  Med: 1.47 Max: 3.37
Current: 0.6
0.38
3.37
PS Ratio 0.18
ACET's PS Ratio is ranked higher than
96% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. ACET: 0.18 )
Ranked among companies with meaningful PS Ratio only.
ACET' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.59 Max: 1.63
Current: 0.18
0.12
1.63
Price-to-Free-Cash-Flow 2.27
ACET's Price-to-Free-Cash-Flow is ranked higher than
94% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. ACET: 2.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACET' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.4  Med: 19.82 Max: 543
Current: 2.27
1.4
543
Price-to-Operating-Cash-Flow 2.06
ACET's Price-to-Operating-Cash-Flow is ranked higher than
93% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. ACET: 2.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACET' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.27  Med: 16.15 Max: 217.3
Current: 2.06
1.27
217.3
EV-to-EBIT -1.56
ACET's EV-to-EBIT is ranked higher than
68% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. ACET: -1.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.2  Med: 11.6 Max: 45.7
Current: -1.56
-2.2
45.7
EV-to-EBITDA -1.84
ACET's EV-to-EBITDA is ranked higher than
88% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. ACET: -1.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.6  Med: 9.55 Max: 22.2
Current: -1.84
-2.6
22.2
EV-to-Revenue 0.50
ACET's EV-to-Revenue is ranked higher than
93% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACET: 0.50 )
Ranked among companies with meaningful EV-to-Revenue only.
ACET' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 0.6 Max: 1.8
Current: 0.5
0.3
1.8
Shiller PE Ratio 45.51
ACET's Shiller PE Ratio is ranked higher than
93% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.11 vs. ACET: 45.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACET' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.18  Med: 21.21 Max: 95
Current: 45.51
11.18
95
Current Ratio 1.12
ACET's Current Ratio is ranked lower than
60% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACET: 1.12 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.08 Max: 4.33
Current: 1.12
1.12
4.33
Quick Ratio 0.79
ACET's Quick Ratio is ranked lower than
65% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. ACET: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.92 Max: 2.76
Current: 0.79
0.79
2.76
Days Inventory 85.47
ACET's Days Inventory is ranked higher than
67% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. ACET: 85.47 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 76.62  Med: 83.66 Max: 87.05
Current: 85.47
76.62
87.05
Days Sales Outstanding 128.83
ACET's Days Sales Outstanding is ranked lower than
76% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. ACET: 128.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 83.21 Max: 149.18
Current: 128.83
61.39
149.18
Days Payable 76.27
ACET's Days Payable is ranked lower than
55% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ACET: 76.27 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.97 Max: 76.27
Current: 76.27
34.34
76.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.12
ACET's Dividend Yield % is ranked higher than
83% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. ACET: 5.12 )
Ranked among companies with meaningful Dividend Yield % only.
ACET' s Dividend Yield % Range Over the Past 10 Years
Min: 0.79  Med: 2.24 Max: 10.36
Current: 5.12
0.79
10.36
3-Year Dividend Growth Rate 2.70
ACET's 3-Year Dividend Growth Rate is ranked lower than
60% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. ACET: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ACET' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -50.8  Med: 6.9 Max: 126.4
Current: 2.7
-50.8
126.4
Forward Dividend Yield % 0.99
ACET's Forward Dividend Yield % is ranked higher than
80% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ACET: 0.99 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.41
ACET's 5-Year Yield-on-Cost % is ranked higher than
82% of the 889 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. ACET: 6.41 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ACET' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.99  Med: 2.8 Max: 12.97
Current: 6.41
0.99
12.97
3-Year Average Share Buyback Ratio -1.50
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ACET: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.4  Med: -0.7 Max: 6.2
Current: -1.5
-4.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.33
ACET's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. ACET: 0.33 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACET' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.3  Med: 1.05 Max: 2.95
Current: 0.33
0.3
2.95
Price-to-Median-PS-Value 0.32
ACET's Price-to-Median-PS-Value is ranked higher than
84% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ACET: 0.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACET' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.84 Max: 2.5
Current: 0.32
0.29
2.5
Earnings Yield (Greenblatt) % -63.09
ACET's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACET: -63.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACET' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -69.2  Med: 8.45 Max: 23.8
Current: -63.09
-69.2
23.8
Forward Rate of Return (Yacktman) % 31.18
ACET's Forward Rate of Return (Yacktman) % is ranked higher than
70% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. ACET: 31.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACET' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.8  Med: 14.3 Max: 31.18
Current: 31.18
0.8
31.18

More Statistics

Revenue (TTM) (Mil) $737.10
EPS (TTM) $ -5.90
Beta1.51
Volatility85.28%
52-Week Range $2.22 - 17.10
Shares Outstanding (Mil)30.79

Analyst Estimate

Jun18 Jun19 Jun20 Jun21
Revenue (Mil $) 712 700 647 626
EBIT (Mil $)
EBITDA (Mil $) 47 21 20 22
EPS ($) 0.78 0.60 0.13 0.21
EPS without NRI ($) 0.78 0.60 0.13 0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.21 0.04 0.04 0.04

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}